Bristol Myers Squibb Strengthens Position in Obstructive Hypertrophic Cardiomyopathy with New Camzyos (mavacamten) Data Presented at ACC 2026
Bristol Myers Squibb has unveiled an extensive body of new clinical and real-world evidence supporting the continued evolution of Camzyos (mavacamten) as a transformative therapy for patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The data will be presented at the American College of Cardiology Annual Scientific Session & Expo 2026, scheduled to take place from March 28 to 30, 2026, in New Orleans.
The presentations highlight a growing and increasingly robust evidence base for Camzyos, encompassing both controlled clinical trial results and real-world patient outcomes. Together, these findings reinforce the therapy’s role in redefining treatment paradigms for oHCM, a chronic and often debilitating cardiovascular condition characterized by thickened heart muscle and obstruction of blood flow from the left ventricle.
A key focus of the data being presented at ACC.26 is the expansion of Camzyos’ potential use beyond adult populations. Among the most anticipated updates is the late-breaking oral presentation of results from the Phase 3 SCOUT-HCM trial. This landmark study represents the first randomized, double-blind, placebo-controlled international trial evaluating a cardiac myosin inhibitor in adolescent patients with symptomatic oHCM. According to the findings, Camzyos successfully met its primary endpoint, along with several important secondary endpoints assessing both efficacy and safety. These results mark a significant milestone, as treatment options for adolescents with oHCM have historically been limited, often focusing primarily on symptom management rather than disease modification.
Cristian Massacesi, MD, Executive Vice President, Chief Medical Officer, and Head of Development at Bristol Myers Squibb, emphasized the importance of these findings in the broader context of cardiovascular care. He noted that Camzyos has already redefined the standard of care for adult patients with oHCM, supported by a growing body of long-term and real-world evidence. The SCOUT-HCM data further suggest that this innovative therapy could extend similar benefits to younger patients, addressing a significant unmet medical need in adolescent populations.
In addition to clinical trial data, Bristol Myers Squibb is presenting multiple analyses derived from real-world studies, offering valuable insights into how Camzyos performs in routine clinical practice. These studies collectively demonstrate consistent effectiveness and a favorable safety profile across diverse patient populations.
One such study, DISCOVER-HCM, is an ongoing observational, multicenter registry that includes both retrospective and prospective data from patients with symptomatic oHCM across the United States and Puerto Rico. Findings from this registry, presented as a moderated poster, indicate that the real-world safety and effectiveness of Camzyos closely mirror the outcomes observed in controlled clinical trials. This alignment between trial data and real-world evidence is particularly important for clinicians, as it reinforces confidence in the therapy’s reliability and reproducibility in everyday practice.
Further real-world insights come from the MARVEL-HCM study, which evaluates the use of Camzyos in U.S.-based patients with symptomatic oHCM. The data from MARVEL-HCM highlight sustained and consistent improvements in both clinical and hemodynamic parameters. Notably, the study underscores the importance of accurately identifying obstructive physiology in patients, including through provocation testing. Proper characterization of hypertrophic cardiomyopathy subtypes is essential for optimizing treatment strategies and ensuring that patients receive therapies aligned with current clinical guidelines.
Another significant contribution comes from the COMPASS-HCM study, a prospective observational analysis focusing on patient-reported outcomes. This study demonstrates that patients treated with Camzyos experience rapid and meaningful improvements in quality of life and overall health status, with measurable benefits emerging as early as two weeks after treatment initiation. These findings emphasize not only the clinical efficacy of the therapy but also its tangible impact on patients’ daily lives, as reflected in their own reported experiences.
In addition to these primary analyses, several supplementary abstracts provide deeper insights into specific patient subgroups and clinical scenarios. For example, one poster examines the effectiveness and safety of Camzyos in patients with a high prevalence of atrial fibrillation, a common comorbidity in oHCM. Another analysis explores sex-based differences in baseline characteristics and treatment outcomes, contributing to a more nuanced understanding of how different patient populations respond to therapy.
A qualitative interview study further enriches the dataset by capturing patient perspectives on what constitutes meaningful improvement in oHCM. These insights are particularly valuable in the context of patient-centered care, helping to align clinical endpoints with outcomes that matter most to patients.
The breadth of data being presented at ACC.26 reflects Bristol Myers Squibb’s comprehensive and sustained commitment to advancing the science of hypertrophic cardiomyopathy. By integrating findings from randomized clinical trials, observational registries, and patient-reported outcomes, the company is building one of the most mature and extensive evidence bases for any therapy in this disease area.
As the understanding of oHCM continues to evolve, therapies like Camzyos are playing a central role in shifting the treatment paradigm from symptom control toward targeted, disease-modifying approaches. The inclusion of adolescent data from SCOUT-HCM further signals a potential expansion of this paradigm, offering hope for earlier and more effective intervention in younger patients.
Overall, the data being presented at the American College of Cardiology’s 2026 meeting reinforce Camzyos’ position as a cornerstone therapy in oHCM management. With consistent efficacy, a well-characterized safety profile, and demonstrated benefits across both clinical and real-world settings, the therapy continues to shape the future of care for patients living with this complex cardiovascular condition.
About CAMZYOS® (mavacamten)
CAMZYOS® (mavacamten) is the most extensively studied cardiac myosin inhibitor (CMI), approved by regulatory bodies in more than 60 countries and regions across five continents worldwide. In the U.S., CAMZYOS is indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms. In the European Union, CAMZYOS is indicated for the treatment of symptomatic (NYHA, class II-III) oHCM in adult patients.
A selective, reversible, allosteric inhibitor of cardiac myosin, CAMZYOS targets hypercontractility, the source of oHCM. Reduction in cardiac contractility with CAMZYOS treatment leads to reduced LVOT obstruction, improved energy consumption, and lower cardiac filling pressures in oHCM patients. These effects translate to improvements in symptoms for patients with symptomatic oHCM, enabling them to be more active in their daily lives. CAMZYOS can be used with or without background therapies, including for newly diagnosed patients.
CAMZYOS is supported by the largest body of worldwide evidence in the CMI treatment class, with up to five years of follow up across multiple long-term evidence and real-world studies, demonstrating the consistent and sustained benefits of CAMZYOS to improve symptoms and impact cardiac structure. CAMZYOS has been prescribed by more than 4,500 healthcare providers (HCPs) to more than 22,000 patients in the U.S. alone.
Source Link:https://news.bms.com/
